410544-19-3 Usage
General Description
4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE is a chemical compound that belongs to the pyrazolopyridine class of molecules. This organic heterotricyclic compound is characterized by its fused pyridine and pyrazole rings, giving it unique structural and chemical properties. Due to its heterocyclic nature, 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINE is of interest in medicinal chemistry and drug discovery, as it can exhibit diverse biological activities. It may have potential applications in pharmaceuticals, agrochemicals, and other industries due to its unique structure and potential pharmacological properties. Further research and development are needed to fully understand the potential of this compound in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 410544-19-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,0,5,4 and 4 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 410544-19:
(8*4)+(7*1)+(6*0)+(5*5)+(4*4)+(3*4)+(2*1)+(1*9)=103
103 % 10 = 3
So 410544-19-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H9N3/c1-2-7-3-5-4-8-9-6(1)5/h4,7H,1-3H2,(H,8,9)
410544-19-3Relevant articles and documents
Compound as potassium channel modulator
-
, (2018/07/30)
The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.
Calcitonin gene related peptide receptor antagonists
-
, (2008/06/13)
The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.